Stifel Upgrades Alkermes
Among the posters, Alkermes presented results from a real-world, retrospective study of healthcare resource utilization (HCRU) and treatment patterns in patients with schizophrenia and patients with ...
Zacks.com on MSN13d
Alkermes' Q3 Earnings & Revenues Fall Shy of Estimates, Stock DownAlkermes plc ALKS reported adjusted earnings from continuing operations of 73 cents per share for third-quarter 2024, which ...
Alkermes (NASDAQ:ALKS – Get Free Report) had its target price dropped by equities researchers at The Goldman Sachs Group from ...
Robert W. Baird analyst Joel Beatty maintained a Buy rating on Alkermes (ALKS – Research Report) yesterday and set a price target of ...
Taking the first step to start addiction treatment is an uphill battle, but what can prove to be harder is keeping on a ...
Alkermes (NASDAQ:ALKS – Get Free Report)‘s stock had its “overweight” rating reiterated by equities researchers at Piper ...
In a report released yesterday, Charles Duncan from Cantor Fitzgerald initiated coverage with a Buy rating on Alkermes (ALKS – Research ...
BofA analyst Jason Gerberry lowered the firm’s price target on Alkermes (ALKS) to $28 from $29 and keeps a Neutral rating on the shares. The company reported a relatively in-line Q3 and ...
Third Quarter 2024 Results Key Financial Results Revenue: US$378.1m (flat on 3Q 2023).
DUBLIN (AP) — DUBLIN (AP) — Alkermes PLC (ALKS) on Thursday reported third-quarter profit of $92.4 million. On a per-share basis, the Dublin-based company said it had profit of 55 cents.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback